A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
A phase 3 trial of Equecabtagene autoleucel, Daratumumab, Pomalidomide in multiple myeloma, run by Nanjing IASO Biotechnology Co., Ltd., now recruiting.
Overview
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) is a phase 3 interventional study registered as NCT06464991 by Nanjing IASO Biotechnology Co., Ltd., with 240 participants planned, started 2024-03-27 and due to reach its primary completion in 2027-08. Interventions recorded: Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Pomalidomide, Bortezomib, Daratumumab, Dexamethasone.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Pomalidomide, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.